Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer
about
Prognostic Value of Basic Fibroblast Growth Factor (bFGF) in Lung Cancer: A Systematic Review with Meta-AnalysisBRCA1-associated protein 1 deficiency in lung adenocarcinoma predicts poor outcome and increased tumor invasionDirect anti-metastatic efficacy by the DNA enzyme Dz13 and downregulated MMP-2, MMP-9 and MT1-MMP in tumours.Fast, hungry and unstable: finding the Achilles' heel of small-cell lung cancer.FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.VEGF blocking therapy in the treatment of cancer.The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literatureImmunohistochemical markers of prognosis in non-small cell lung cancer: a review and proposal for a multiphase approach to marker evaluationNovel targeted agents in the treatment of lung cancer.Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lungPrognostic impact of serum and tissue MMP-9 in non-small cell lung cancer: a systematic review and meta-analysisImmunohistochemical expression of basic fibroblast growth factor and fibroblast growth factor receptors 1 and 2 in the pathogenesis of lung cancerThe role of matrix metalloproteinase 2 on the survival of patients with non-small cell lung cancer: a systematic review with meta-analysis.Protocatechuic acid inhibits lung cancer cells by modulating FAK, MAPK, and NF-κB pathways.Cannabinoid receptor-2 agonist inhibits macrophage induced EMT in non-small cell lung cancer by downregulation of EGFR pathway.Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302).[Correlation of postoperative serum VEGF levels with platelet counts in non-small cell lung cancer].
P2860
Q26772984-23482502-5136-4827-8BAA-7C6F3E45CE4DQ28387249-C9B37234-D90F-40EA-9B3C-74FF1B98880AQ33816168-887DFCBE-6CDB-43E4-8535-06CDECB09CA5Q34013850-76A9C211-1F5F-485F-9A3E-98D18F226028Q34419405-E607C9CB-042A-43C7-828D-E261DD1420ECQ35093616-A1FA87C2-1392-4604-ACC3-CEF113CD6703Q35216052-C33207C1-70C2-4440-9DE7-288F36778982Q35770249-D0FBD841-E35D-473D-B809-4A3A38DEE6FAQ35790783-950AAE27-D363-4194-8859-0F7EB21B27D5Q36262168-E231D2BF-29B2-44D2-A9F9-D6682B8A0DCCQ37109786-21B20021-E6D9-4F3F-8B3C-32CFBA705462Q37413167-9FACC62B-35E3-48B3-8FEB-102DB9FAED78Q37731543-A964E667-509E-4585-A740-E7A57A36F2DDQ38943879-D6ECBC14-A729-43D9-8652-E8C377504700Q40133231-CB17DA7E-AA2B-4C58-B75F-6000856ED058Q42738385-4A31B633-8E8F-45D3-A899-BEDD7779403AQ50041855-FE10C200-2552-4154-9787-8B1F44C66768Q55430606-9564B56A-7806-4A04-AD09-D8B2B1303FBF
P2860
Influence of angiogenetic factors and matrix metalloproteinases upon tumour progression in non-small-cell lung cancer
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@ast
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@en
type
label
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@ast
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@en
prefLabel
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@ast
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@en
P2093
P2860
P356
P1476
Influence of angiogenetic fact ...... in non-small-cell lung cancer
@en
P2093
P2860
P2888
P304
P356
10.1054/BJOC.2001.2137
P407
P577
2001-11-01T00:00:00Z
P5875
P6179
1028558487